Opexa Therapeutics (ACER) and The Competition Critical Comparison
Opexa Therapeutics (NASDAQ: ACER) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Opexa Therapeutics to similar companies based on the strength of its profitability, valuation, dividends, earnings, analyst recommendations, risk and institutional ownership.
Volatility & Risk
Opexa Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Comparatively, Opexa Therapeutics’ rivals have a beta of 5.60, suggesting that their average share price is 460% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Opexa Therapeutics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Opexa Therapeutics Competitors||848||3199||11599||230||2.71|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.47%. Given Opexa Therapeutics’ rivals higher possible upside, analysts clearly believe Opexa Therapeutics has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Opexa Therapeutics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Opexa Therapeutics||$2.90 million||-$7.97 million||-2.59|
|Opexa Therapeutics Competitors||$284.28 million||$34.29 million||134.10|
Opexa Therapeutics’ rivals have higher revenue and earnings than Opexa Therapeutics. Opexa Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
0.3% of Opexa Therapeutics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 6.9% of Opexa Therapeutics shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Opexa Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Opexa Therapeutics Competitors||-5,349.08%||-434.35%||-39.98%|
Opexa Therapeutics rivals beat Opexa Therapeutics on 7 of the 9 factors compared.
About Opexa Therapeutics
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.